Vir Biotechnology Inc (VIR) Stock
Key stats
- Market cap
- $2.25B
- Price / Earnings ratio
- -12.2x
- EPS (TTM)
- -$1.24
- Volume
- Loading
- 52-week high
- $14.38
- 52-week low
- $5.32
Source: third-party data provider, as of November 13, 2026
Compare with VIR
Recent news

VIR Stock Soars Over 10% Overnight, Eyes Best Year Ever — Hepatitis Win Sparks Buyout Buzz And Bigger Bullish Bets
VIR Stock Soars Over 10% Overnight, Eyes Best Year Ever — Hepatitis Win Sparks Buyout Buzz And Bigger Bullish Bets
VIR

Why Did MRNA, XERS, VIR Stocks Surge To 52-Week Highs Last Week?
Why Did MRNA, XERS, VIR Stocks Surge To 52-Week Highs Last Week?
VIR

Dow, S&P 500, Nasdaq Futures Rebound After Sharp AI Selloff Last Week: NVDA, AMD, VIR, SNDK In Focus
Dow, S&P 500, Nasdaq Futures Rebound After Sharp AI Selloff Last Week: NVDA, AMD, VIR, SNDK In Focus
VIR

Vir Biotechnology to Participate in the Jefferies 2026 London Healthcare Conference
Vir Biotechnology to Participate in the Jefferies 2026 London Healthcare Conference
VIR
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 63.13
- MACD 12/26/9
- 0.53
- EMA 9 of MACD
- 0.30
- MACD histogram
- 0.23
- SMA 50
- $11.16
- Price above SMA 50
- EMA 50
- $11.15
- Price above EMA 50
- SMA 200
- $9.73
- Price above SMA 200
- EMA 200
- $9.57
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.60 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

VIR Stock Soars Over 10% Overnight, Eyes Best Year Ever — Hepatitis Win Sparks Buyout Buzz And Bigger Bullish Bets
VIR Stock Soars Over 10% Overnight, Eyes Best Year Ever — Hepatitis Win Sparks Buyout Buzz And Bigger Bullish Bets
VIR

Why Did MRNA, XERS, VIR Stocks Surge To 52-Week Highs Last Week?
Why Did MRNA, XERS, VIR Stocks Surge To 52-Week Highs Last Week?
VIR

Dow, S&P 500, Nasdaq Futures Rebound After Sharp AI Selloff Last Week: NVDA, AMD, VIR, SNDK In Focus
Dow, S&P 500, Nasdaq Futures Rebound After Sharp AI Selloff Last Week: NVDA, AMD, VIR, SNDK In Focus
VIR

Vir Biotechnology to Participate in the Jefferies 2026 London Healthcare Conference
Vir Biotechnology to Participate in the Jefferies 2026 London Healthcare Conference
VIR

Vir Biotechnology Announces Appointment of Suzanne Topalian to its Board of Directors
Vir Biotechnology Announces Appointment of Suzanne Topalian to its Board of Directors
VIR

Vir Biotechnology to Host Conference Call for Third Quarter 2026 Financial Results
Vir Biotechnology to Host Conference Call for Third Quarter 2026 Financial Results
VIR

Stocktwits Biotech Dealmaker: Gilead, AstraZeneca And Roche Chase Pipeline Expansion Over Buyouts
Stocktwits Biotech Dealmaker: Gilead, AstraZeneca And Roche Chase Pipeline Expansion Over Buyouts
VIR

Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors
Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors
VIR

Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD's The Liver Meeting® 2026
Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD's The Liver Meeting® 2026
VIR

Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer
Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer
VIR
News tone: automated (AI) classification of the article's content, not a price prediction.
About Vir Biotechnology Inc
Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting SARS-CoV-2, hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Marianne De Backer M.B.A., M.Sc., Ph.D. | President, CEO & Director | 1969 |
| Mr. Aziz Sawaf C.F.A., M.B.A. | Executive VP, CFO & Principal Financial Officer | 1982 |
| Ms. Vanina de Verneuil J.D. | Executive VP, General Counsel & Corporate Secretary | 1979 |
| Dr. Lawrence Corey M.D. | Co-Founder & Scientific Advisor | 1947 |
| Dr. Louis J. Picker M.D. | Co-Founder & Scientific Advisor | — |
| Mr. Brent Sabatini C.P.A., M.B.A. | Senior VP, Principal Accounting Officer & Chief Accounting Officer | 1974 |
| Dr. Maninder Hora Ph.D. | Executive VP & Chief Technical Operations Officer | 1954 |
| Dr. Jennifer Eileen Towne Ph.D. | Executive VP & Chief Scientific Officer | — |
| Dr. Kiki Patel Pharm.D. | Head of Investor Relations | — |
| Ms. Carolyn Wang | Senior Vice President of Corporate Communications | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 63.13
- MACD 12/26/9
- 0.53
- EMA 9 of MACD
- 0.30
- MACD histogram
- 0.23
- SMA 50
- $11.16
- Price above SMA 50
- EMA 50
- $11.15
- Price above EMA 50
- SMA 200
- $9.73
- Price above SMA 200
- EMA 200
- $9.57
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $22.00
- Average
- $24.75
- High
- $28.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +44.2 | -10.9 | ||||||||||
| 2022 | -12.9 | -28.4 | +7.2 | -19.6 | +23.7 | -0.2 | +7.5 | -13.4 | -20.8 | +10.1 | +25.3 | -6.4 |
| 2023 | +18.6 | -21.8 | +3.0 | +8.0 | +6.0 | -8.8 | -42.8 | -11.1 | -25.1 | -11.8 | +21.8 | +3.8 |
| 2024 | -10.6 | +23.2 | -9.9 | -17.1 | +17.5 | -16.3 | +11.6 | -15.1 | -3.7 | -0.9 | -14.0 | -9.9 |
| 2025 | +43.1 | -15.9 | -18.2 | -1.0 | -18.7 | -0.6 | -0.8 | -1.8 | +14.2 | +4.6 | +14.6 | -0.7 |
| 2026 | +25.3 | +17.9 | -4.1 | +13.3 | -4.6 | +12.8 | -9.4 | +22.9 | -3.9 | +0.1 | +19.4 |



